Q00987 (MDM2_HUMAN) Homo sapiens (Human)
E3 ubiquitin-protein ligase Mdm2 UniProtKBInterProSTRINGInteractive Modelling
491 aa; Sequence (Fasta) ; (Isoform 2; Isoform 3; Isoform 4; Isoform 5; Isoform 6; Isoform 7; Isoform 8; Isoform 9; Isoform 10; Isoform 11)
It is possible new templates exist for this target since these models were created.
Available Structures
142 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Structure of complex of MDM2(3-109) and P73 TAD(10-25) |
Heteromer O15350; | 100 | ||||
| Green fluorescent protein linked MTide-02 inhibitor in complex with mdm2 |
Heteromer | 100 | 1×GOL; 2×PO4; 1×PG4; | |||
| Structure of the MDM2 P53 binding domain in complex with H103, an all-D Helicon Polypeptide, altern… |
Heteromer | 100 | 6×EDO; 1×SO4; 1×DMS; 1×WHL; | |||
| MDM2 bound CueO-PM2 sensor |
Heteromer P36649; | 100 | ||||
| Structure of the MDM2 P53 binding domain in complex with H101, an all-D Helicon Polypeptide |
Heteromer | 100 | 1×CL; 1×WHL; | |||
| Crystal structure of beta-catenin and the MDM2 p53-binding domain in complex with H330, a Helicon P… |
Heteromer P35222; | 100 | 1×WHL; | |||
| Crystal structure of the computationally designed chemically disruptable heterodimer LD6-MDM2 |
Heteromer Q328D2; | 100 | ||||
| Crystal structure of beta-catenin and the MDM2 p53-binding domain in complex with H329, a Helicon P… |
Heteromer P35222; | 100 | 1×WHL; | |||
| Crystal structure of beta-catenin and the MDM2 p53-binding domain in complex with H332, a Helicon P… |
Heteromer P35222; | 100 | 1×WHL; | |||
| Crystal structure of p53 epitope-scaffold based on a inhibitor of cysteine proteases in complex wit… |
Heteromer | 100 | 7×CL; 2×SO4; 1×GOL; | |||
| MDM2 BOUND TO THE TRANSACTIVATION DOMAIN OF P53 |
Heteromer P04637; | 100 | ||||
| Crystal structure of beta-catenin and the MDM2 p53-binding domain in complex with H333, a Helicon P… |
Heteromer P35222; | 100 | 1×WHL; | |||
| Crystal structure of human MDM2 in complex with a potent miniature protein inhibitor (18-residues) |
Heteromer | 100 | 3×ACT; 1×CL; | |||
| Crystal Structure of an MDM2/P53 Peptide Complex |
Heteromer P04637; | 97.59 | 1×SO4; | |||
| Solution structure of Hdm2 with engineered cyclotide |
Heteromer | 100 | ||||
| Crystal Structure of the MDM2-MDMX RING Domain Heterodimer |
Heteromer O15151; | 100 | 4×ZN; | |||
| Structure of MDM2-MDMX-UbcH5B-ubiquitin complex |
Heteromer O15151; P0CG47; P62837; | 100 | 4×ZN; 1×SO4; | |||
| Crystal structure of human MDM2 RING domain homodimer bound to UbcH5B-Ub |
Heteromer P62837; P62979; | 100 | 4×ZN; 4×CL; 2×NO3; | |||
| Crystal structure of human MDM2-G443T RING domain homodimer bound to UbcH5B-Ub (Crystal form 1) |
Heteromer P0CG47; P62837; | 98.39 | 4×CL; 2×ZN; 2×EDO; | |||
| Crystal structure of human MDM2-G443T RING domain homodimer bound to UbcH5B-Ub (Crystal form 2) |
Heteromer P0CG47; P62837; | 98.39 | 1×CL; 2×ZN; 2×EDO; | |||
| Crystal Structure of the MDM2-MDMX RING Domain Heterodimer |
Heteromer O15151; | 100 | 4×ZN; | |||
| Crystal structure of human MDM2-RPL11 |
Heteromer P62913; | 100 | 1×IMD; 1×BME; 2×ZN; | |||
| human MDM2-5S RNP |
Heteromer P46777; P62913; | 100 | 1×ZN; | |||
| Human 14-3-3 sigma in complex with human MDM2 peptide |
Heteromer P31947; | 100.0 | 2×GOL; 2×PEG; 2×CL; 4×MG; | |||
| Crystal Structure of the USP7:Hdm2(PSTS) complex |
Heteromer Q93009; | 100 | ||||
| 14-3-3 sigma in complex with hDM2-186 peptide |
Heteromer P31947; | 100 | 6×IOD; | |||
| The Crystal Structure of the N-terminal domain of HAUSP/USP7 complexed with mdm2 peptide 147-150 |
Heteromer Q93009; | 100 | ||||
| CRYSTAL STRUCTURE OF HUMAN MDM2 WITH AN IMIDAZOLINE INHIBITOR | homo-3-mer | 98.82 | 5×IMZ; | |||
| Structure of MDM2 with low molecular weight inhibitor with aliphatic linker. | homo-2-mer | 100 | 2×6GG; | |||
| Structure of Human MDM2 in complex with a Benzodiazepine Inhibitor | homo-2-mer | 98.96 | 2×DIZ; | |||
| Structure of a stapled peptide antagonist bound to Nutlin-resistant Mdm2. | homo-2-mer | 98.95 | ||||
| Structure of MDM2 with low molecular weight inhibitor with aliphatic linker. | homo-2-mer | 100 | 2×6GG; | |||
| Inhibitor of MDM2-p53 Interaction | homo-2-mer | 98.92 | 2×TVH; | |||
| X-ray structure of the p53-MDM2 inhibitor NMI801 bound to HDM2 at 2.1A resolution | homo-2-mer | 100 | 2×H0W; | |||
| Structure of hMDM2 in complex with Nutlin-3a-aa | homo-2-mer | 100 | 2×BME; 2×M0L; | |||
| Crystal structure of human MDM2 with a 12-mer peptide inhibitor PMI (N8A mutant) | homo-2-mer | 100 | 2×CL; | |||
| Structure of hDM2 with Dimer Inducing Indolyl Hydantoin RO-2443 | homo-2-mer | 98.81 | 2×03M; | |||
| Crystal structure of human MDM2 in complex with a 12-mer peptide inhibitor | homo-2-mer | 100 | 2×GAI; | |||
| Crystal structure of human MDM2 in complex with D-peptide inhibitor (DPMI-alpha) | homo-2-mer | 100 | 1×SO4; 1×CL; | |||
| Solution Structure of Hdm2 RING Finger Domain | homo-2-mer | 100 | 4×ZN; | |||
| NMR Structure of Mdm2 (6-125) with Pip-1 | monomer | 100 | 1×13Q; | |||
| NMR structure of unliganded MDM2 | monomer | 100 | ||||
| Ordering of the N Terminus of Human MDM2 by Small Molecule Inhibitors | monomer | 100 | 1×0Y7; | |||
| Co-crystal Structure of MDM2 in Complex with AM-7209 | monomer | 100 | 1×3UD; 2×SO4; | |||
| Co-Crystal Structure of MDM2 with Inhibitor Compound 4 | monomer | 100 | 1×2U0; 2×SO4; | |||
| MDM2 in complex with SAR405838 | monomer | 100.0 | 1×7HC; 1×SO4; 3×GOL; | |||
| Co-Crystal Structure of MDM2 with Inhbitor Compound 3 | monomer | 100 | 1×2U5; 2×SO4; | |||
| Co-Crystal Structure of MDM2 with Inhbitor Compound 46 | monomer | 100 | 1×2U6; 1×SO4; | |||
| Co-Crystal Structure of MDM2 with Inhibitor Compound 47 | monomer | 100 | 1×2U1; | |||
| Chemical Shift Assignments for MIP and MDM2 in bound state | monomer | 100 | ||||
| Structure of the stapled peptide YS-01 bound to MDM2 | monomer | 97.92 | ||||
| Structure of the stapled peptide YS-02 bound to MDM2 | monomer | 97.92 | ||||
| HDM2 in complex with a 3,3-Disubstituted Piperidine | monomer | 97.92 | 1×62T; 1×SO4; | |||
| Structure of MDM2 with low molecular weight inhibitor | monomer | 100 | 1×B5K; | |||
| Human MDM2 liganded with a 12mer peptide inhibitor (pDI6W) | monomer | 100 | ||||
| Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-bas… | monomer | 100 | 1×6ZT; 1×SO4; 1×CL; | |||
| Structure-activity studies of Mdm2/Mdm4-binding stapled peptides comprising non-natural amino acids | monomer | 98.95 | ||||
| HDM2 in complex with compound 63 | monomer | 100 | 1×1I9; 2×GOL; 1×CL; | |||
| HDM2 in complex with compound 56 | monomer | 100 | 1×1I0; | |||
| Structure of the MDM2 P53 binding domain in complex with H103, an all-D Helicon Polypeptide | monomer | 100 | 2×SO4; 1×CL; 1×WHL; | |||
| Structure of Mdm2 with low molecular weight inhibitor | monomer | 100 | 1×4NJ; | |||
| HDM2 in complex with compound 62 | monomer | 100 | 1×1I3; 4×SO4; | |||
| Discovery of New Natural-product-inspired Spiro-oxindole Compounds as Orally Active Inhibitors of t… | monomer | 100 | 3×GOL; 1×SO4; 1×6SS; | |||
| HDM2 (17-111, WILDTYPE) COMPLEXED WITH COMPOUND 9 AT 1.13A; Structural states of Hdm2 and HdmX: X-r… | monomer | 100 | 1×HTZ; 3×CL; | |||
| HDM2 (17-111, WILDTYPE) COMPLEXED WITH COMPOUND 10 AT 1.21A; Structural states of Hdm2 and HdmX: X-… | monomer | 100 | 1×HU8; | |||
| Novel Spiro[3H-indole-3,2 -pyrrolidin]-2(1H)-one Inhibitors of the MDM2-p53 Interaction: HDM2 (MDM2… | monomer | 100 | 1×6SJ; 3×SO4; | |||
| Novel Spiro[3H-indole-3,2 -pyrrolidin]-2(1H)-one Inhibitors of the MDM2-p53 Interaction: HDM2 (MDM2… | monomer | 100 | 1×6ST; 1×ZN; 1×SO4; | |||
| Crystal structure of MDM2 in complex with compound 13. | monomer | 100 | 1×H28; 1×GOL; 2×SO4; | |||
| In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor | monomer | 100 | 1×EYH; 1×CL; | |||
| Crystal structure of MDM2 with Brigimadlin | monomer | 100 | 1×G7I; | |||
| HDM2 (17-111, WILD TYPE) COMPLEXED WITH NVP-HDM201 AT 1.56A | monomer | 100 | 1×9QW; 1×CL; | |||
| Structure of human MDM2 protein in complex with Mi-63-analog | monomer | 100 | 1×MI6; | |||
| Exhaustive Fluorine Scanning towards Potent p53-MDM2 Antagonist | monomer | 100 | 1×07G; | |||
| co-crystal structure of MDM2 (17-111) in complex with compound 25 | monomer | 100 | 1×2SW; | |||
| co-crystal structure of MDM2 (17-111) with compound 16, {(3R,5R,6S)-5-(3-CHLOROPHENYL)-6-(4-CHLOROP… | monomer | 100.0 | 1×35S; | |||
| Co-crystal structure of MDM2 with inhibitor (2'S,3R,4'S,5'R)-N-(2-aminoethyl)-6-chloro-4'-(3-chloro… | monomer | 100.0 | 1×1MT; | |||
| Novel Spiro[3H-indole-3,2 -pyrrolidin]-2(1H)-one Inhibitors of the MDM2-p53 Interaction: HDM2 (MDM2… | monomer | 100 | 1×6SK; 1×SO4; | |||
| HDM2 in complex with a 3,3-Disubstituted Piperidine | monomer | 97.85 | 1×62R; 1×SO4; | |||
| co-crystal structure of MDM2(17-111) in complex with compound 48 | monomer | 100 | 1×2TZ; | |||
| Discovery of NVP-CGM097 - a highly potent and selective MDM2 inhibitor undergoing phase 1 clinical … | monomer | 100 | 1×4T4; 1×CL; | |||
| The Central Valine Concept Provides an Entry in a New Class of Non Peptide Inhibitors of the P53-MD… | monomer | 98.92 | 1×BLF; | |||
| Structure of a novel submicromolar MDM2 inhibitor | monomer | 100 | 1×Y30; 2×SO4; | |||
| Structure of Mdm2 with low molecular weight inhibitor. | monomer | 100 | 1×4NX; | |||
| crystal structure of MDM2 with chromenotriazolopyrimidine 1 | monomer | 100 | 1×YIN; | |||
| Co-Crystal Structure of MDM2 with Inhibitor Compound 49 | monomer | 100.0 | 1×2U7; | |||
| Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interaction | monomer | 98.92 | 1×2V8; | |||
| Co-crystal structure of MDM2 with inhibitor (2R,3E)-2-[(2S,3R,6S)-2,3-bis(4-chlorophenyl)-6-(4-fluo… | monomer | 100.0 | 1×1MQ; | |||
| Crystal Structure of HDM2 in complex with Nutlin-3a | monomer | 100 | 1×NUT; 1×SO4; 1×CL; 1×IOD; | |||
| HDM2 in complex with a beta-hairpin | monomer | 100 | 2×SO4; 1×MPO; | |||
| Inhibitor of MDM2-p53 Interaction | monomer | 97.83 | 1×DMS; 2×EDO; 3×SO4; 1×TVK; | |||
| Co-crystal structure of MDM2 with Inhibitor Compound 4 | monomer | 100.0 | 1×2TW; | |||
| Structure of a stapled peptide bound to MDM2 | monomer | 97.83 | 1×O9E; | |||
| Inhibitor of MDM2-p53 Interaction | monomer | 97.83 | 2×DMS; 1×EDO; 2×SO4; 1×TUW; | |||
| crystal structure of compound 16 bound to MDM2(17-111), {(3R,5R,6S)-5-(3-CHLOROPHENYL)-6-(4-CHLOROP… | monomer | 100 | 1×35T; | |||
| Inhibitor of MDM2-p53 Interaction | monomer | 97.83 | 3×EDO; 1×U3Z; | |||
| crystal structure of MDM2 (17-111) in complex with compound 29 (AM-8553) | monomer | 100 | 1×0R3; | |||
| HDM2 (17-111, WILD TYPE) COMPLEXED WITH COMPOUND 11 AT 2.0A; Structural states of Hdm2 and HdmX: X-… | monomer | 100 | 1×HRH; | |||
| Inhibitor of MDM2-p53 Interaction | monomer | 97.83 | 2×SO4; 1×TUZ; | |||
| Inhibitor of MDM2-p53 Interaction | monomer | 97.83 | 1×SO4; 1×TV5; | |||
| Co-crystal structure of MDM2 with inhibitor {(2S,5R,6S)-6-(3-chlorophenyl)-5-(4-chlorophenyl)-4-[(2… | monomer | 100.0 | 1×1MY; | |||
| Crystal Structure of HDM2 in complex with Caylin-1 | monomer | 100 | 3×CL; 2×NA; 1×SO4; 1×AU0; 2×DMS; | |||
| Crystal Structure of an MDM2/Nutlin-3a complex | monomer | 97.8 | 1×NUT; 1×SO4; | |||
| Discovery of NVP-CGM097 - a highly potent and selective MDM2 inhibitor undergoing phase 1 clinical … | monomer | 100.0 | 1×4TH; 1×CL; | |||
| Crystal structure of Mdm2 bound to a stapled peptide | monomer | 97.8 | 1×FL5; | |||
| crystal structure of MDM2 (17-111) in complex with compound 23 | monomer | 100.0 | 1×0R2; 1×SO4; | |||
| X-ray structure of Mdm2 with modified p53 peptide | monomer | 100 | ||||
| Structure of a novel submicromolar MDM2 inhibitor | monomer | 100 | 1×TJ2; 2×K; | |||
| HDM2 in complex with compound 2 | monomer | 97.75 | 1×1GI; 1×SO4; 1×CIT; | |||
| Crystal structure of HIS6-tagged Mdm2 with nutlin-3a | monomer | 100 | 1×NUT; | |||
| MDM2 in complex with an 8-mer p53 peptide analogue | monomer | 100 | ||||
| Structure of human MDM2 in complex with an optimized p53 peptide | monomer | 100 | 1×SO4; | |||
| The 1.25A Crystal structure of His6-tagged Mdm2 in complex with nutlin-3a | monomer | 100 | 1×NUT; | |||
| Structure of the MDM2 P53 binding domain in complex with H102, an all-D Helicon Polypeptide | monomer | 100 | 4×EDO; 1×CL; 2×GOL; 1×WHL; 1×IMD; | |||
| MDM2 bound with a peptoid | monomer | 100 | 1×UAC; 7×CL; | |||
| Crystal structure of hDM2 in complex with a C-terminal triurea capped peptide chimera foldamer. | monomer | 98.85 | ||||
| HDM2 (17-111, WILD TYPE) COMPLEXED WITH COMPOUND 12 AT 1.8A; Structural states of Hdm2 and HdmX: X-… | monomer | 100 | 1×HRE; 2×SO4; | |||
| Structure of human MDM2 in complex with high affinity peptide | monomer | 100 | ||||
| Structure of the Stapled p53 Peptide Bound to Mdm2 | monomer | 100 | 5×CL; | |||
| X-RAY STRUCTURE OF HDM2/CMR19 AT 1.45A: Discovery, X-ray structure and CPP-conjugation enabled upta… | monomer | 100 | 2×SO4; | |||
| Mdm2 in complex with a D amino Acid Containing Stapled Peptide | monomer | 100 | ||||
| Structure of a novel submicromolar MDM2 inhibitor | monomer | 100 | 2×28W; | |||
| HDM2 in complex with a 3,3-Disubstituted Piperidine | monomer | 97.67 | 1×62Q; | |||
| CRYSTAL STRUCTURE OF HUMAN MDM2 IN COMPLEX WITH D-PEPTIDE INHIBITOR (DPMI-OMEGA) | monomer | 100 | 1×PEG; 1×IPA; 2×CL; | |||
| MDM2 bound to inhibitor | monomer | 100 | ||||
| Macrocyclization of an all-D linear peptide improves target affinity and imparts cellular activity:… | monomer | 100 | ||||
| Crystal structure of human MDM2 in complex with a 12-mer lysine-cysteine side chain dithiocarbamate… | monomer | 100 | ||||
| Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Pro… | monomer | 98.82 | 1×EPE; 1×DMS; 1×M9E; | |||
| Crystal structure of human mdm2 with a dihydroimidazothiazole inhibitor | monomer | 98.82 | 1×LTZ; 1×SO4; | |||
| Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Pro… | monomer | 98.82 | 1×M9H; | |||
| Co-crystal structure of MDM2 with inhibitor (2S,5R,6S)-2-benzyl-5,6-bis(4-bromophenyl)-4-methylmorp… | monomer | 100 | 1×1MN; 1×SO4; | |||
| Structure of human MDM2 protein in complex with a small molecule inhibitor | monomer | 98.82 | 1×K23; 1×SO4; | |||
| Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Pro… | monomer | 98.82 | ||||
| Co-crystal structure of MDM2 with inhibitor (2S,5R,6S)-2-benzyl-5,6-bis(4-chlorophenyl)-4-methylmor… | monomer | 100 | 1×1MO; 2×SO4; | |||
| Crystal structure of human mdm2 with a dihydroimidazothiazole inhibitor | monomer | 98.82 | 1×VZV; | |||
| Crystal structure of human MDM2 in complex with a trifluoromethylated D-peptide inhibitor | monomer | 100 | 1×SO4; | |||
| Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with… | monomer | 98.81 | 2×4SS; | |||
| Human MDM2 liganded with a 12mer peptide inhibitor (pDIQ) | monomer | 100 | 1×EDO; | |||
| Structure of the Stapled Peptide Bound to Mdm2 | monomer | 97.59 | 1×P07; | |||
| CRYSTAL STRUCTURE OF HUMAN MDM2 IN COMPLEX WITH 12-MER PEPTIDE INHIBITOR M3 | monomer | 100 | ||||
| Crystal structure of human MDM2 complexed with D-peptide (12 residues) | monomer | 100 | ||||
| Solution structure of the C4 zinc-finger domain of HDM2 | monomer | 100 | 1×ZN; | |||
| Solution structure of the C4 zinc-finger domain of HDM2 | monomer | 100 | 1×ZN; | |||
2 SWISS-MODEL models
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 5j7f.2.A | homo-2-mer | 0.81 | 2×6GG; | 100.00 | ||
| 7ahz.1.A | homo-2-mer | 0.76 | 4×ZN; | 85.29 | ||
18 SWISS-MODEL models built on isoform sequence
| Isoform | Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|---|
| Isoform 2 | 6sqp.1.B | monomer | 0.68 | 2×ZN; | 91.18 | ||
| Isoform 3 | 6sqp.1.B | monomer | 0.70 | 2×ZN; | 91.18 | ||
| Isoform 3 | 4xxb.1.B | monomer | 0.53 | 1×ZN; | 97.78 | ||
| Isoform 4 | 7ahy.1.A | homo-2-mer | 0.76 | 4×ZN; | 85.29 | ||
| Isoform 4 | 4xxb.1.B | monomer | 0.52 | 1×ZN; | 96.38 | ||
| Isoform 5 | 7bj0.1.A | monomer | 0.77 | 85.71 | |||
| Isoform 5 | 6sqp.1.B | monomer | 0.66 | 2×ZN; | 91.18 | ||
| Isoform 6 | 5mnj.1.C | monomer | 0.67 | 2×ZN; | 100.00 | ||
| Isoform 7 | 5j7f.2.A | homo-2-mer | 0.74 | 84.95 | |||
| Isoform 8 | 7ahz.1.A | homo-2-mer | 0.75 | 4×ZN; | 85.29 | ||
| Isoform 8 | 1ttv.1.A | monomer | 0.62 | 73.21 | |||
| Isoform 9 | 7ah2.1.A | monomer | 0.71 | 2×ZN; | 79.31 | ||
| Isoform 9 | 5j7f.2.A | monomer | 0.54 | 100.00 | |||
| Isoform 10 | 5j7f.2.A | homo-2-mer | 0.81 | 2×6GG; | 100.00 | ||
| Isoform 10 | 7ahz.1.A | homo-2-mer | 0.77 | 4×ZN; | 85.29 | ||
| Isoform 11 | 5j7f.2.A | homo-2-mer | 0.81 | 2×6GG; | 100.00 | ||
| Isoform 11 | 7ahz.1.A | homo-2-mer | 0.75 | 4×ZN; | 85.29 | ||
| Isoform 11 | 4xxb.1.B | monomer | 0.56 | 1×ZN; | 100.00 | ||